Regeneron Pharmaceuticals, Inc. (REGN)

579.81
NASDAQ
Prev Close 575.73
Day Low/High 575.12 / 582.72
52 Wk Low/High 299.22 / 664.64
Exchange NASDAQ
Shares Outstanding 106.39B
Market Cap 61.25B
P/E Ratio 22.32
Div & Yield N.A. (N.A)
Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver

Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver

U.S. stocks gave up earlier gains as the energy sector continued to sell off despite relatively stable crude prices on Tuesday.

Double Top Could Spell Double Trouble for Regeneron

Double Top Could Spell Double Trouble for Regeneron

The biopharmaceutical company is in for a deeper bear phase. 

Regeneron downgraded at Canaccord

Cramer: This Is Where I Say I Was Wrong

Cramer: This Is Where I Say I Was Wrong

My speculation on Fitbit and Alcoa didn't work out.

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.

Have a CIGAR, You'll Go Far in 2016

Have a CIGAR, You'll Go Far in 2016

5 biotech stocks that could outperform the overall market in 2016.

Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE

Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE

TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.

Don't Abandon the Biotech Ship

Don't Abandon the Biotech Ship

There's too much good out there.

Ailing Stocks Are Making a Recovery

Ailing Stocks Are Making a Recovery

Apple tops the list, but it has lots of company.

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.

This Acronym Really Stinks

This Acronym Really Stinks

Don't use it as a gauge of market strength.

Stocks Slightly Lower Amid Yellen's Rate-Hike Hints

Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...

Rotation Is Enough to Make Your Head Spin

Rotation Is Enough to Make Your Head Spin

Bad news isn't always a bad thing.

Anatomy of a Rally: Simpler Than You Think

Anatomy of a Rally: Simpler Than You Think

Understanding why stocks act the way they do.

Grasping at Growth: The Hunt Is On

Grasping at Growth: The Hunt Is On

Once again, buyers are going for the gusto.

5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher

5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher

The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.

Regeneron Has More Upside to Go

Regeneron Has More Upside to Go

The stock shows bullish momentum and could climb 5%.

We're Feeling Better About Growth Stocks

We're Feeling Better About Growth Stocks

Amazon is among the indicators.

Eli Lilly's Stock Is Worth a Chance Below $80

The company's stock will likely be among the first to turn.

Plenty of Good News -- If You Look

Plenty of Good News -- If You Look

Not all growth is hated today.

Drug Stocks' Earnings Power Won't Go Away

Before you sell them, ask yourself at what multiple you sell.

Regeneron downgraded at Morgan Stanley

Jim Cramer: Could Glencore Be the Next Long Term Capital?

Jim Cramer: Could Glencore Be the Next Long Term Capital?

Jim Cramer answered viewers’ Twitter (TWTR) questions from the floor of the Stock Exchange and said he's not assuaged by Glencore's (GLCNF) comments that it is ‘operationally and financially robust.'

These Biotech Trades are a Great Rx

These Biotech Trades are a Great Rx

Hillary Clinton has created some good short-term opportunities.

It May Be Early, but Check Out the Moves in These Stocks

High-growth, REIT and consumer names clearly want to go higher.

Regeneron Chart Looks Rejuvenated

Regeneron Chart Looks Rejuvenated

Shares appear ready to return to previous highs.

Not the Kind of Waves You Want to Make

Not the Kind of Waves You Want to Make

On days like this, bizarre action is the norm.

It's OK, Market: Some (But Not All) Is Forgiven

It's OK, Market: Some (But Not All) Is Forgiven

But this might be a good time to sell.

This Volatility in the Indices Is Just Plain Phony

It's just machine to machine, but we are haunted by 2008.

Build a Core Position in Biotech Intrexon at These Lower Prices

Build a Core Position in Biotech Intrexon at These Lower Prices

Following a 40% decline, now looks good for scaling into the stock.